![](https://investorshub.advfn.com/uicon/716239.png?cb=1669318942)
Monday, October 02, 2023 11:44:23 AM
Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate
• Study was conducted in Spain with women who declined standard of care surgery
• ProSense is approved for the treatment of breast cancer throughout the European Union
CAESAREA, Israel, Oct. 2, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that new data was presented at the European Society of Breast Imaging ("EUSOBI") Scientific Meeting in Valencia, Spain by Lucía Graña-López, MD, PhD, principal investigator of the independent, non-sponsored study.
![](http://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg)
In a poster titled "Cryoablation for the treatment of early-stage breast cancer in patients who decline surgery" Dr. Graña-López presented the findings of her study conducted at University Hospital Lucus Augusti in Lugo, Spain which used ProSense for cryoablation treatment of 31 patients with early-stage breast cancer who declined surgery, the standard of care. Dr. Graña-López, a radiologist who specializes in breast and women's imaging, is Head of the Breast Unit at University Hospital Lucus Augusti.
All patients were diagnosed with biopsy-proven early breast cancer (cT1-2cN0-1cM0) with a median tumor size of 24 mm, ranging between 6 to 45 mm. Patients were followed by mammography and ultrasound every 6 months for 2 years and annually thereafter. The median follow-up was 10 months, with a range of 0 to 40 months. Cancer progression was observed in 1 patient (1/31, 3.2%). No major complications were seen and the procedure was well tolerated by all patients.
The study concluded that cryoablation could be an alternative treatment to surgery for breast cancer in patients who reject surgery. Underscoring the need for such an alternative, the poster presented that breast cancer is the most commonly diagnosed malignant neoplasm worldwide and that while surgery is the standard of care for early-stage breast cancer, some patients, most of them elderly, decline standard of care surgery and prefer a less invasive option.
Dr. Graña-López commented, "I've been effectively using ProSense for cryoablation in women who decline surgery with very good results. I think that soon, cryoablation will be a real alternative to surgery in early-stage breast cancer in post-menopausal women. Beyond breast cancer, I believe ProSense can have an impact on the way cancers of the kidney, lung, and thyroid gland are treated."
"Doctors around the world are using ProSense with women who want an alternative to surgery for early- stage breast cancer, and it's highly encouraging to see these physicians publish and share their results with the medical community," stated IceCure's CEO, Eyal Shamir. "These data are very much in line with the interim results of our ICE3 study, the largest of its kind in the U.S., which is expected to conclude in the first quarter of 2024."
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
https://www.nasdaq.com/press-release/independent-study-validates-icecures-prosense-cryoablation-is-safe-effective
$ICCM
Don't invest what you can't afford to lose. Always do your own DD. INV4$
Recent ICCM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/22/2024 01:00:49 PM
- 99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society • PR Newswire (US) • 07/22/2024 12:30:00 PM
- IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification • PR Newswire (US) • 07/19/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/16/2024 08:35:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/09/2024 12:45:14 PM
- European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer • PR Newswire (US) • 07/09/2024 12:30:00 PM
- U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes • PR Newswire (US) • 07/01/2024 12:30:00 PM
- IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 • PR Newswire (US) • 06/18/2024 12:30:00 PM
- Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function • PR Newswire (US) • 06/12/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 12:50:02 PM
- FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan • PR Newswire (US) • 06/04/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 12:45:28 PM
- IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 • PR Newswire (US) • 05/28/2024 12:30:00 PM
- U.S. Futures Present Mixed Pre-Market Performance, Oil Prices Surge • IH Market News • 05/28/2024 11:31:04 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/21/2024 08:10:17 PM
- IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024 • PR Newswire (US) • 05/21/2024 12:30:00 PM
- IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase • PR Newswire (US) • 05/20/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2024 12:40:03 PM
- Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally • PR Newswire (US) • 05/07/2024 12:30:00 PM
- IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer • PR Newswire (US) • 04/15/2024 12:35:00 PM
- IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance • PR Newswire (US) • 04/03/2024 12:30:00 PM
- U.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge Higher • IH Market News • 04/03/2024 11:11:59 AM
- IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes • PR Newswire (US) • 04/02/2024 12:30:00 PM
- IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 • PR Newswire (US) • 03/27/2024 12:30:00 PM
- IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy • PR Newswire (US) • 03/19/2024 12:30:00 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM